Nephros (NEPH) Competitors $1.59 +0.05 (+3.25%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends NEPH vs. SSKN, APT, LUCD, NTRB, APYX, CTSO, NXL, CLGN, MLSS, and BLACShould you be buying Nephros stock or one of its competitors? The main competitors of Nephros include STRATA Skin Sciences (SSKN), Alpha Pro Tech (APT), Lucid Diagnostics (LUCD), Nutriband (NTRB), Apyx Medical (APYX), Cytosorbents (CTSO), Nexalin Technology (NXL), CollPlant Biotechnologies (CLGN), Milestone Scientific (MLSS), and Bellevue Life Sciences Acquisition (BLAC). These companies are all part of the "medical equipment" industry. Nephros vs. STRATA Skin Sciences Alpha Pro Tech Lucid Diagnostics Nutriband Apyx Medical Cytosorbents Nexalin Technology CollPlant Biotechnologies Milestone Scientific Bellevue Life Sciences Acquisition STRATA Skin Sciences (NASDAQ:SSKN) and Nephros (NASDAQ:NEPH) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, valuation, analyst recommendations, media sentiment, community ranking and dividends. Does the MarketBeat Community believe in SSKN or NEPH? STRATA Skin Sciences received 210 more outperform votes than Nephros when rated by MarketBeat users. Likewise, 63.90% of users gave STRATA Skin Sciences an outperform vote while only 43.33% of users gave Nephros an outperform vote. CompanyUnderperformOutperformSTRATA Skin SciencesOutperform Votes22363.90% Underperform Votes12636.10% NephrosOutperform Votes1343.33% Underperform Votes1756.67% Do analysts rate SSKN or NEPH? Nephros has a consensus target price of $5.00, suggesting a potential upside of 214.47%. Given Nephros' stronger consensus rating and higher possible upside, analysts plainly believe Nephros is more favorable than STRATA Skin Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score STRATA Skin Sciences 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Nephros 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders & institutionals believe in SSKN or NEPH? 32.4% of STRATA Skin Sciences shares are owned by institutional investors. Comparatively, 41.1% of Nephros shares are owned by institutional investors. 39.0% of STRATA Skin Sciences shares are owned by company insiders. Comparatively, 4.1% of Nephros shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Which has preferable earnings and valuation, SSKN or NEPH? Nephros has lower revenue, but higher earnings than STRATA Skin Sciences. Nephros is trading at a lower price-to-earnings ratio than STRATA Skin Sciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSTRATA Skin Sciences$33.36M0.39-$10.83M-$2.66-1.16Nephros$14.24M1.18-$1.58M-$0.09-17.67 Is SSKN or NEPH more profitable? Nephros has a net margin of -6.86% compared to STRATA Skin Sciences' net margin of -28.72%. Nephros' return on equity of -11.39% beat STRATA Skin Sciences' return on equity.Company Net Margins Return on Equity Return on Assets STRATA Skin Sciences-28.72% -69.33% -17.55% Nephros -6.86%-11.39%-8.30% Does the media refer more to SSKN or NEPH? In the previous week, STRATA Skin Sciences had 8 more articles in the media than Nephros. MarketBeat recorded 9 mentions for STRATA Skin Sciences and 1 mentions for Nephros. Nephros' average media sentiment score of 0.98 beat STRATA Skin Sciences' score of -0.03 indicating that Nephros is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment STRATA Skin Sciences 1 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Nephros 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has more volatility and risk, SSKN or NEPH? STRATA Skin Sciences has a beta of 1.32, suggesting that its stock price is 32% more volatile than the S&P 500. Comparatively, Nephros has a beta of 1.19, suggesting that its stock price is 19% more volatile than the S&P 500. SummaryNephros beats STRATA Skin Sciences on 11 of the 18 factors compared between the two stocks. Ad Weiss RatingsTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.This could be his favorite coin. Get Nephros News Delivered to You Automatically Sign up to receive the latest news and ratings for NEPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NEPH vs. The Competition Export to ExcelMetricNephrosSurgical & medical instruments IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.24M$4.41B$5.01B$8.81BDividend YieldN/A41.16%5.16%4.06%P/E Ratio-17.6724.82134.3717.77Price / Sales1.1847.021,158.6875.18Price / CashN/A51.8733.5332.53Price / Book2.044.974.674.68Net Income-$1.58M$13.76M$119.07M$226.08M7 Day Performance0.63%-1.08%-1.83%-1.04%1 Month Performance10.42%0.58%-3.62%1.04%1 Year Performance-27.73%50.91%31.63%26.28% Nephros Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NEPHNephros2.1854 of 5 stars$1.59+3.2%$5.00+214.5%-24.3%$16.24M$14.24M-17.6730Gap UpSSKNSTRATA Skin Sciences0.583 of 5 stars$3.09+2.0%N/A-40.7%$12.64M$33.36M0.00120APTAlpha Pro TechN/A$5.29-1.1%N/A+11.1%$58.13M$59.29M14.28120LUCDLucid Diagnostics3.2198 of 5 stars$1.00+4.2%$3.69+268.8%-23.1%$56.72M$2.43M0.0070NTRBNutriband0.6276 of 5 stars$4.98+1.4%N/A+125.3%$54.53M$2.09M0.0010APYXApyx Medical1.4466 of 5 stars$1.40+9.4%N/A-39.1%$52.70M$48.54M-1.58270CTSOCytosorbents1.2772 of 5 stars$0.92-4.2%$2.00+118.4%-34.6%$52.47M$33.79M-2.54186Analyst ForecastGap DownNXLNexalin Technology0.7353 of 5 stars$3.80-2.1%$3.00-21.1%+1,051.5%$49.90M$110,000.000.003CLGNCollPlant Biotechnologies1.8582 of 5 stars$4.23+1.0%$11.00+160.0%-24.2%$48.43M$10.96M-2.7570Upcoming EarningsMLSSMilestone Scientific2.1701 of 5 stars$0.68+9.7%$1.25+84.4%-15.8%$48.30M$9.83M0.0030Analyst ForecastBLACBellevue Life Sciences AcquisitionN/A$11.60-0.6%N/A+11.0%$46.86MN/A0.00N/A Related Companies and Tools Related Companies STRATA Skin Sciences Competitors Alpha Pro Tech Competitors Lucid Diagnostics Competitors Nutriband Competitors Apyx Medical Competitors Cytosorbents Competitors Nexalin Technology Competitors CollPlant Biotechnologies Competitors Milestone Scientific Competitors Bellevue Life Sciences Acquisition Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:NEPH) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nephros, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nephros With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
